Relay Therapeutics exits its Q1 earnings week with an unusual split: the Street just raised price targets across the board, yet shorts are adding and the stock is down 7% on the week.
The analyst move this week is the headline. Three firms raised targets in the 24 hours following earnings — Barclays lifted to $27 from $21, Raymond James moved to $26 from $23, and Citizens nudged to $21 from $19. All maintained positive ratings. That follows a wave of target increases on April 28, when Goldman Sachs, Wells Fargo, and Oppenheimer all revised up after a prior catalyst. The consensus now has 11 buy-equivalent ratings, zero holds, and a mean target of $22.83 — roughly 89% above the current $12.07 close. There is no dissent on the Street. The analyst recommendation differential ranks in the 98th percentile universe-wide, a signal of exceptionally lopsided bullish conviction.
Short interest tells the contrarian story. Bears hold 16.6% of the free float — essentially unchanged from where the earnings preview noted it, and up 24% over the past month. Days to cover run at 8.7, so unwinding the position at normal volume would take nearly two weeks. Yet the borrow market remains relaxed. Availability is around 634% — more than six shares available to borrow for every one already lent — and the cost to borrow has drifted only modestly higher to 0.63%, roughly 20% above where it was a week ago but still far from squeeze territory. Short sellers are building positions, but they face no mechanical pressure to cover. The ORTEX short score of 64.9 has been easing slightly over the past two weeks from its recent high of 66.9 on May 8.
Options positioning is also notably calm given the price drop. The put/call ratio is running at 0.16, barely above its 20-day average of 0.14 and well below the 52-week high of 0.55. Call flow continues to dominate — options traders are not hedging into any near-term catalyst in any material way. That call skew, alongside the unanimous analyst conviction, makes the week's 7% decline look more like a post-earnings exhale than a sentiment break.
The earnings reaction itself was muted. The Q1 print on May 5 produced a 1.3% one-day decline. A prior event in March generated a 3.7% gain and a 9.2% five-day follow-through. The pattern is inconsistent. The next event is scheduled for June 9, which gives positioning roughly three weeks to reset.
On the institutional side, Adage Capital added 2.09 million shares in the quarter to March, FMR (Fidelity) added 3.53 million shares in the period to April, and Casdin Capital added 1.42 million. SB Investment Advisers remains the largest holder at 14.6% of shares. The accumulation pattern among active managers sits in contrast to the short build — a standoff between institutional longs and systematic bears that mirrors the analyst-versus-short divergence visible across the positioning data. Insider activity has been confined to routine CFO sales, the most recent a $228k sell by Thomas Catinazzo on May 14 — nothing that reads as a signal in either direction.
What to watch into June 9 is whether the gap between the $12.07 price and the $22.83 mean target begins to close, or whether the short build that ran through April and May continues to exert pressure on a stock where the borrow market gives bears every reason to stay patient.
See the live data behind this article on ORTEX.
Open RLAY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
